000			03503nam a22003615i 4500
001			394869
003			ES-MaUEC
005			20230102123205.0
007			cr nn 008mamaa
008			220805s2022 sz | s |||| 0|eng d
020			_a9783030971823
024	7		_a10.1007/978-3-030-97182-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aNeuroproteomics as a Tool for Understanding Schizophrenia _cedited by Daniel Martins-de-Souza
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (VIII, 143 páginas) _b12 ilustraciones, 11 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aProteomics Metabolomics Interactomics and Systems Biology _x2730-6224 _v1400
505	0		_a1. Postmortem brains: what can proteomics tell us about the sources of schizophrenia? -- 2. What can we learn from animal models to study schizophrenia? -- 3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell -- 4. Schizophrenia outside the brain -- 5. Molecular features triggered by antipsychotic medication in brain cells -- 6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia -- 7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia -- 8. Metabolomics: A powerful tool to understand the schizophrenia biology -- 9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia -- 10. Proteomics and schizophrenia: the evolution of a great partnership.
520			_aOver the past decade, neuroproteomics has shed light on the molecular features of schizophrenia by depicting biological processes involved with its establishment, maintenance and treatment. These studies have also pointed to potential biomarkers applicable to diagnosis and medication monitoring. Edited by a leader in the field of neuroproteomics with contributions from subject experts, this new volume will address recent findings and compile evidence from difference perspectives-such as human samples, animal models, pluripotent stem cell-derived in vitro pre-clinical models-and provide findings to inform the development of innovative future treatment strategies. This volume will be useful for a broad audience of researchers and professionals, including biologists, neurologists, psychiatrists, analytical chemists, and pharmacists, among others. Provides comprehensive overview on how neuroproteomics helped depicting the molecular features of schizophrenia Addresses biological processes, treatment strategies, and recent research findings associated to schizophrenia Addresses current research challenges, future strategies, and clinical applications.
700	1		_aMartins-de-Souza, Daniel _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030971816
776	0	8	_iPrinted edition: _z9783030971830
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-97182-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_BiomedLife_2022
999			_c394869 _d394869